NASDAQ:NVLN - Novelion Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.84 -0.06 (-6.67 %) (As of 05/24/2019 01:17 AM ET)Previous Close$0.8948Today's Range$0.83 - $0.919252-Week Range$0.70 - $4.79Volume163,955 shsAverage Volume282,878 shsMarket Capitalization$15.98 millionP/E RatioN/ADividend YieldN/ABeta2.18 ProfileAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada. Receive NVLN News and Ratings via Email Sign-up to receive the latest news and ratings for NVLN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVLN Previous Symbol CUSIPN/A CIK827809 Webhttp://www.novelion.com/ Phone617-500-7867Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.21Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$130.43 million Price / Sales0.12 Cash FlowN/A Price / Cash FlowN/A Book Value($6.25) per share Price / Book-0.13Profitability EPS (Most Recent Fiscal Year)($5.76) Net Income$-108,330,000.00 Net Margins-79.43% Return on EquityN/A Return on Assets-26.13%Miscellaneous Employees109 Outstanding Shares19,044,000Market Cap$15.98 million Next Earnings Date8/6/2019 (Estimated) OptionableOptionable Novelion Therapeutics (NASDAQ:NVLN) Frequently Asked Questions What is Novelion Therapeutics' stock symbol? Novelion Therapeutics trades on the NASDAQ under the ticker symbol "NVLN." How were Novelion Therapeutics' earnings last quarter? Novelion Therapeutics Inc (NASDAQ:NVLN) issued its quarterly earnings data on Thursday, March, 14th. The biotechnology company reported ($1.03) EPS for the quarter, missing the Zacks' consensus estimate of ($0.90) by $0.13. The biotechnology company had revenue of $40.71 million for the quarter, compared to analysts' expectations of $40.90 million. View Novelion Therapeutics' Earnings History. When is Novelion Therapeutics' next earnings date? Novelion Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Novelion Therapeutics. What price target have analysts set for NVLN? 2 analysts have issued 1-year price targets for Novelion Therapeutics' stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate Novelion Therapeutics' share price to reach $5.00 in the next year. This suggests a possible upside of 496.0% from the stock's current price. View Analyst Price Targets for Novelion Therapeutics. What is the consensus analysts' recommendation for Novelion Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novelion Therapeutics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novelion Therapeutics. Has Novelion Therapeutics been receiving favorable news coverage? News articles about NVLN stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novelion Therapeutics earned a media sentiment score of 1.9 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days. Who are some of Novelion Therapeutics' key competitors? Some companies that are related to Novelion Therapeutics include IMMUTEP LTD/S (IMMP), Insys Therapeutics (INSY), Elite Pharmaceuticals (ELTP), Eyenovia (EYEN), Aquinox Pharmaceuticals (AQXP), Alimera Sciences (ALIM), Agile Therapeutics (AGRX), IVERIC bio (ISEE), Ophthotech (OPHT), Novan (NOVN), Avadel Pharmaceuticals (AVDL), Seelos Therapeutics (SEEL), AEterna Zentaris (AEZS), Oramed Pharmaceuticals (ORMP) and Proteostasis Therapeutics (PTI). What other stocks do shareholders of Novelion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novelion Therapeutics investors own include Aralez Pharmaceuticals (ARLZ), Amicus Therapeutics (FOLD), Zynerba Pharmaceuticals (ZYNE), Progenics Pharmaceuticals (PGNX), Synergy Pharmaceuticals (SGYP), Biocept (BIOC), Celldex Therapeutics (CLDX), Melinta Therapeutics (MLNT), Novavax (NVAX) and Rigel Pharmaceuticals (RIGL). Who are Novelion Therapeutics' key executives? Novelion Therapeutics' management team includes the folowing people: Mr. Benjamin S. Harshbarger, Interim CEO, Gen. Counsel & Corp. Sec. (Age 50)Mr. Michael D. Price, Exec. VP & CFO (Age 61)Mr. Roger W. Louis, Global Chief Compliance Officer and Head of R&D (Age 63)Ms. Barbara Y. Chan, VP & Chief Accounting Officer (Age 55)Ms. Amanda Murphy, Director of Investor Relations & Corp. Communications Who are Novelion Therapeutics' major shareholders? Novelion Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include EdgePoint Investment Group Inc. (12.72%) and Broadfin Capital LLC (3.83%). Company insiders that own Novelion Therapeutics stock include Donald K Stern and Healthcare Master Fun Broadfin. View Institutional Ownership Trends for Novelion Therapeutics. Which institutional investors are selling Novelion Therapeutics stock? NVLN stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC. View Insider Buying and Selling for Novelion Therapeutics. Which institutional investors are buying Novelion Therapeutics stock? NVLN stock was acquired by a variety of institutional investors in the last quarter, including EdgePoint Investment Group Inc.. View Insider Buying and Selling for Novelion Therapeutics. How do I buy shares of Novelion Therapeutics? Shares of NVLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Novelion Therapeutics' stock price today? One share of NVLN stock can currently be purchased for approximately $0.8389. How big of a company is Novelion Therapeutics? Novelion Therapeutics has a market capitalization of $15.98 million and generates $130.43 million in revenue each year. The biotechnology company earns $-108,330,000.00 in net income (profit) each year or ($5.76) on an earnings per share basis. Novelion Therapeutics employs 109 workers across the globe. What is Novelion Therapeutics' official website? The official website for Novelion Therapeutics is http://www.novelion.com/. How can I contact Novelion Therapeutics? Novelion Therapeutics' mailing address is 1800 - 510 WEST GEORGIA STREET, VANCOUVER A1, V6B 0M3. The biotechnology company can be reached via phone at 617-500-7867 or via email at [email protected] MarketBeat Community Rating for Novelion Therapeutics (NASDAQ NVLN)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 158 (Vote Outperform)Underperform Votes: 199 (Vote Underperform)Total Votes: 357MarketBeat's community ratings are surveys of what our community members think about Novelion Therapeutics and other stocks. Vote "Outperform" if you believe NVLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVLN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: Systematic Risk and Investors Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.